Cargando…

Occurrence of senescence-escaping cells in doxorubicin-induced senescence is enhanced by PD0332991, a cyclin-dependent kinase 4/6 inhibitor, in colon cancer HCT116 cells

Cancer treatment induces cellular senescence, and it is considered to be one of the factors that determines treatment outcome. Senescence can be efficiently induced in cultured cells by DNA-damaging drugs, including doxorubicin (DOX), cisplatin and etoposide. Cells in senescence cease proliferation;...

Descripción completa

Detalles Bibliográficos
Autores principales: Kitada, Kunio, Pu, Fengling, Toi, Masakazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312925/
https://www.ncbi.nlm.nih.gov/pubmed/30655877
http://dx.doi.org/10.3892/ol.2018.9657
_version_ 1783383852433014784
author Kitada, Kunio
Pu, Fengling
Toi, Masakazu
author_facet Kitada, Kunio
Pu, Fengling
Toi, Masakazu
author_sort Kitada, Kunio
collection PubMed
description Cancer treatment induces cellular senescence, and it is considered to be one of the factors that determines treatment outcome. Senescence can be efficiently induced in cultured cells by DNA-damaging drugs, including doxorubicin (DOX), cisplatin and etoposide. Cells in senescence cease proliferation; however, it has been demonstrated that colonies that are formed from cells escaping senescence appear in drug-induced senescence; however, the conditions influencing the emergence of such senescence-escaping cells (SECs) remain unclear. The present study aimed to investigate the relevance of the cell cycle phase and colony formation in the DOX-induced senescence of human colon cancer HCT116 cells. After release from serum starvation in the presence of DOX, cells synchronously progressed through the cell cycle and were arrested in the G(1) and G(2)/M phases. The ratio of G(1) cells arrested immediately by the treatment of G(1) phase cells was positively associated with the number of colony-forming cells. A procedure increasing G(1)-treated G(1)-arrested cells enhanced colony formation. Co-treatment of PD0332991 with DOX slowed progression of cells in the G(1) phase resulting in enhanced colony formation from the increased G(1)-treated G(1)-arrested cells. These results may provide useful insights into understanding the emergence of SECs in drug-induced senescence.
format Online
Article
Text
id pubmed-6312925
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-63129252019-01-17 Occurrence of senescence-escaping cells in doxorubicin-induced senescence is enhanced by PD0332991, a cyclin-dependent kinase 4/6 inhibitor, in colon cancer HCT116 cells Kitada, Kunio Pu, Fengling Toi, Masakazu Oncol Lett Articles Cancer treatment induces cellular senescence, and it is considered to be one of the factors that determines treatment outcome. Senescence can be efficiently induced in cultured cells by DNA-damaging drugs, including doxorubicin (DOX), cisplatin and etoposide. Cells in senescence cease proliferation; however, it has been demonstrated that colonies that are formed from cells escaping senescence appear in drug-induced senescence; however, the conditions influencing the emergence of such senescence-escaping cells (SECs) remain unclear. The present study aimed to investigate the relevance of the cell cycle phase and colony formation in the DOX-induced senescence of human colon cancer HCT116 cells. After release from serum starvation in the presence of DOX, cells synchronously progressed through the cell cycle and were arrested in the G(1) and G(2)/M phases. The ratio of G(1) cells arrested immediately by the treatment of G(1) phase cells was positively associated with the number of colony-forming cells. A procedure increasing G(1)-treated G(1)-arrested cells enhanced colony formation. Co-treatment of PD0332991 with DOX slowed progression of cells in the G(1) phase resulting in enhanced colony formation from the increased G(1)-treated G(1)-arrested cells. These results may provide useful insights into understanding the emergence of SECs in drug-induced senescence. D.A. Spandidos 2019-01 2018-11-01 /pmc/articles/PMC6312925/ /pubmed/30655877 http://dx.doi.org/10.3892/ol.2018.9657 Text en Copyright: © Kitada et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Kitada, Kunio
Pu, Fengling
Toi, Masakazu
Occurrence of senescence-escaping cells in doxorubicin-induced senescence is enhanced by PD0332991, a cyclin-dependent kinase 4/6 inhibitor, in colon cancer HCT116 cells
title Occurrence of senescence-escaping cells in doxorubicin-induced senescence is enhanced by PD0332991, a cyclin-dependent kinase 4/6 inhibitor, in colon cancer HCT116 cells
title_full Occurrence of senescence-escaping cells in doxorubicin-induced senescence is enhanced by PD0332991, a cyclin-dependent kinase 4/6 inhibitor, in colon cancer HCT116 cells
title_fullStr Occurrence of senescence-escaping cells in doxorubicin-induced senescence is enhanced by PD0332991, a cyclin-dependent kinase 4/6 inhibitor, in colon cancer HCT116 cells
title_full_unstemmed Occurrence of senescence-escaping cells in doxorubicin-induced senescence is enhanced by PD0332991, a cyclin-dependent kinase 4/6 inhibitor, in colon cancer HCT116 cells
title_short Occurrence of senescence-escaping cells in doxorubicin-induced senescence is enhanced by PD0332991, a cyclin-dependent kinase 4/6 inhibitor, in colon cancer HCT116 cells
title_sort occurrence of senescence-escaping cells in doxorubicin-induced senescence is enhanced by pd0332991, a cyclin-dependent kinase 4/6 inhibitor, in colon cancer hct116 cells
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312925/
https://www.ncbi.nlm.nih.gov/pubmed/30655877
http://dx.doi.org/10.3892/ol.2018.9657
work_keys_str_mv AT kitadakunio occurrenceofsenescenceescapingcellsindoxorubicininducedsenescenceisenhancedbypd0332991acyclindependentkinase46inhibitorincoloncancerhct116cells
AT pufengling occurrenceofsenescenceescapingcellsindoxorubicininducedsenescenceisenhancedbypd0332991acyclindependentkinase46inhibitorincoloncancerhct116cells
AT toimasakazu occurrenceofsenescenceescapingcellsindoxorubicininducedsenescenceisenhancedbypd0332991acyclindependentkinase46inhibitorincoloncancerhct116cells